Moderna Stock Plunges as Company Slashes 2025 Revenue Forecast and Announces Major Cost Cuts

Moderna (NASDAQ: MRNA) shares tumbled 18% in premarket trading on Monday after the biotechnology company significantly lowered its 2025 revenue forecast and announced substantial cost-cutting measures. The company now expects 2025 revenue to range between $1.5 billion and $2.5 billion, with most earnings concentrated in the second half of the year.

The revised forecast represents a notable reduction from previous estimates, primarily due to declining demand for its COVID-19 vaccines and slower-than-expected adoption of its respiratory syncytial virus (RSV) shot. This adjustment reflects the challenging transition Moderna faces in the post-pandemic market landscape, where vaccine demand has significantly decreased from its peak during the COVID-19 crisis.

In response to these challenges, Moderna has outlined an aggressive cost-reduction strategy. The company plans to cut cash expenses by $1 billion in 2025, followed by an additional $500 million in reductions planned for 2026. These measures aim to maintain financial stability as the company navigates through this period of reduced revenue.

Despite these challenges, Moderna reported relatively stable performance for 2024, with product sales reaching $3.0-3.1 billion and an ending cash balance of approximately $9.5 billion. However, the company projects its cash balance will decrease to around $6.0 billion by the end of 2025.

Moderna’s Chief Financial Officer, Jamey Mock, identified several key challenges affecting the company’s outlook. These include increased competition in the COVID-19 vaccine market, where Moderna’s U.S. market share declined to 40% by the end of 2024. The company also faces headwinds from declining vaccination rates, which dropped approximately 7% in the U.S. retail market during fall 2024 compared to the previous year.

Looking ahead, Moderna remains focused on diversifying its product portfolio. The company anticipates several significant milestones across ten prioritized programs, including up to three potential approvals in 2025 and six registrational data readouts. Key developments include the FDA review of its next-generation COVID-19 vaccine (mRNA-1283) with a PDUFA date of May 31, 2025, and positive Phase 3 data for its flu/COVID combination vaccine.

The company’s stock performance has reflected these challenges, with shares experiencing significant volatility. Earlier this month, the stock had surged over 12% following news of the first confirmed death from H5N1 bird flu in the United States. However, this gain was short-lived as investors focused on the broader challenges facing the company.

Despite the current headwinds, some analysts remain optimistic about Moderna’s long-term prospects. The consensus price target among analysts suggests potential upside, though opinions remain mixed regarding the company’s near-term outlook. The success of Moderna’s pipeline developments and its ability to execute its cost-reduction strategy while maintaining innovation will be crucial factors in determining its future performance.